{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"INCB054828"},{"type":"USBrandName","name":"Pemazyre"},{"type":"Synonym","name":"FGFR inhibitor INCB054828"},{"type":"CASRegistryName","name":"1513857-77-6"},{"type":"ChemicalStructureName","name":"2H-pyrrolo(3',2':5,6)pyrido(4,3-d)pyrimidin-2-one, 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-1,3,4,7-tetrahydro-8-(4-morpholinylmethyl)-"}],"definition":{"html":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. Pemigatinib binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation, migration, and survival.","text":"An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. Pemigatinib binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation, migration, and survival."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/pemigatinib","text":"Pemigatinib"},"nciConceptId":"C121553","nciConceptName":"Pemigatinib","termId":770381,"name":"pemigatinib","firstLetter":"p","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"pemigatinib"}],"links":null}